TOLREMO Therapeutics Strengthens Leadership with Key Appointments as TT125-802 Shows Clinical Promise
Key Insights
TOLREMO therapeutics (search) has appointed Alessandra Cesano, MD, PhD, to its Board of Directors and named Florian D. Vogl, MD, PhD, as Chief Medical Officer to strengthen leadership capabilities.
The leadership changes follow promising clinical data presentation at ASCO 2025, where TT125-802 demonstrated significant clinical activity as the first CBP/p300 (search) inhibitor to show efficacy in solid tumors.
TT125-802 showed rapid, deep and durable objective responses in KRAS-G12C (search) and EGFR (search)-mutant non-small cell lung cancer with a best-in-class safety profile without thrombocytopenia.
TOLREMO therapeutics (search) AG, a clinical-stage biotechnology company developing innovative cancer treatments, announced significant leadership appointments following promising clinical data presentations at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The Basel-based company has appointed Alessandra Cesano, MD, PhD, to its Board of Directors and named Florian D. Vogl, MD, PhD, as Chief Medical Officer.
Leadership Transition Strengthens Strategic Direction
Alessandra Cesano, who has served as Consulting Chief Medical Officer since April 2023, transitions to the Board of Directors role, bringing over 25 years of oncology-focused biopharmaceutical experience. Her extensive background includes board positions at Summit Therapeutics, Puma Biotechnology, and Zymeworks, as well as leadership roles at major pharmaceutical companies including Amgen, Biogen Idec, and GSK.
"I am honored to join TOLREMO's Board of Directors at such a transformative time," said Cesano. "It has been a privilege to contribute to the company's clinical vision and witness the team's strong execution, and I look forward to supporting the company's mission from a strategic perspective as we continue to bring benefit to patients."
Florian D. Vogl assumes the CMO position with over a decade of biopharmaceutical industry experience and deep expertise in oncology and clinical development. His previous roles include CMO positions at Swiss and Australian biotech companies, as well as leadership positions at Amgen and Novartis, where he contributed to the development and practice-changing registration of alpelisib and ribociclib for breast cancer treatment.
Clinical Breakthrough with TT125-802
The leadership appointments come as TOLREMO's clinical candidate, TT125-802, achieved a significant milestone as the first CBP/p300 (search) inhibitor to demonstrate clinical activity in solid tumors. The novel small molecule CBP/p300 bromodomain inhibitor showed rapid, deep and durable objective responses in KRAS-G12C (search)- and EGFR (search)-mutant non-small cell lung cancer (NSCLC) during clinical trials.
Notably, TT125-802 demonstrated a best-in-class safety profile without thrombocytopenia, a common side effect associated with other treatments in this class. The ongoing Phase I study has shown encouraging signs of anti-tumor activity in advanced solid tumors while maintaining excellent tolerability.
Innovative Approach to Cancer Treatment
TOLREMO's therapeutic approach targets non-oncogene addiction in cancer by blocking transcriptional escape pathways that operate parallel to the primary oncogene signaling axis. The company's proprietary phenotypic screening platform has uncovered a novel role for CBP/p300 (search) as an epigenetic master regulator of transcriptional resistance.
"The company's approach of targeting non-oncogene addiction in cancer is scientifically groundbreaking and urgently needed by patients," said Vogl. "I look forward to working with this exceptional team to continue the development of TT125-802 both as monotherapy and combination therapy in solid tumors and multiple myeloma."
Future Clinical Development Plans
TOLREMO's next strategic step involves initiating clinical trials evaluating TT125-802 in combination with targeted therapies in specific advanced tumor indications. The planned studies will focus on EGFR (search)- and KRAS-mutated lung cancer, as well as multiple myeloma, representing significant unmet medical needs in oncology.
The orally available small molecule inhibitor of the bromodomain of CBP/p300 (search) offers significant therapeutic potential both as monotherapy and in combination with targeted therapies across solid tumors and hematological malignancies.
Stefanie Flückiger-Mangual, PhD, CEO and Co-Founder of TOLREMO, commented on the appointments: "We are deeply grateful to Alessandra for her outstanding contributions as Consulting CMO and are thrilled to welcome her to our Board of Directors. Her continued guidance will be invaluable. At the same time, we are excited to have Florian join our leadership team. His appointment strengthens our ability to execute on our mission to bring better cancer therapies to patients."